Over the past several years, benchmarks for molecular diagnostics funding have slipped from $100M-plus (sometimes called "the COVID bubble," which also showed in flying then plunging public company valuations), to the $10M range.
Here's a $100M funding round which is worth noting.
Karius, a Bay Area lab dedicatd to genoimic diagnostics for infectious disease, raises $100M from Khosla Ventures, 5AM Ventures, and Glide Healthcare. Existing investors like Softbank and General Catalyst also participated.
Karius writes,
The investment will enable Karius to extend its reach beyond the 400 U.S. hospitals currently using the Karius Test®, an infectious disease diagnostic test that utilizes genomic analysis and artificial intelligence to detect over 1,000 pathogens from a single blood sample. The funding enables Karius to address increasing demand from healthcare providers to expand access to the Karius Test beyond the hospital setting. Additionally, it will support research into the broader health implications of Karius’ microbial cell-free DNA technology beyond infectious diseases.
Press release here:
Karius Test was also used in a current complex NEJM case study of a difficult infectious disease case. Link here (subscription).
